Human Immunology Biosciences (HI-Bio) is leading clinical immunology into its next chapter with therapies that target cellular drivers of disease. HI-Bio uses a precision medicine approach to deliver therapies for patients with the auto-immune, allergic and inflammatory diseases that can together be referred to as immune-mediated diseases (IMDs).

ARCH Venture Partners

Jeito Capital

Monograph Capital

MorphoSys

Alpha Wave Global

Arkin Holdings

Viking Global Investors

HI-Bio

Last week, members of our team attended the American Society of Nephrology’s annual Kidney Week meeting. We were excited to present final data from the Phase 2 M-PLACE trial of felzartamab in patients with primary membranous nephropathy and engage and learn from other attendees and presenters.
 
Thank you to our collaborators, advisors and everyone who made the conference possible! Read more about the posters and presentations by our team: https://lnkd.in/eCTPMiEg

We are excited to announce that the U.S. Food and Drug Administration has granted Breakthrough Therapy designation for felzartamab for primary membranous nephropathy! 
 
This is a recognition of the promising data we have collected to date and is an important step forward in our work to develop targeted therapies to treat severe immune-mediated diseases. Learn more: https://lnkd.in/e-tfq6h9

Attending the American Society of Nephrology’s Kidney Week? We’re excited to share data on our clinically differentiated anti-CD38 candidate, felzartamab: posters on lupus nephritis study design and on mechanism of action, and an oral presentation with full Phase 2 safety and efficacy data in primary membranous nephropathy.
 
Check out the abstracts here: https://lnkd.in/ep-mzz-j #KidneyWk

We are excited to announce that we have initiated a second clinical-stage program, HIB210, an investigational monoclonal antibody targeting C5aR1. Targeting this receptor has the potential to transform the treatment of a variety of high burden immune-mediated diseases (IMDs) for patients in need.
 
Learn more about this exciting milestone: https://lnkd.in/gcwAjwJy

We are excited to announce that the U.S. Food and Drug Administration has granted orphan drug designation for felzartamab, our investigational agent that is in development for the treatment of primary membranous nephropathy!
 
This is an important step forward in our work to develop targeted therapies to treat rare, immune-mediated diseases. Learn more: https://lnkd.in/eGWyx4C3

Today is the second annual IgAN Awareness Day! IgAN is a rare, immune-mediated disease and we are grateful to investigators for their efforts to bring therapies to patients in need. Thanks to the IGAN Foundation for their work to raise awareness around the disease! #IgANAware

We are thrilled to announce the appointment of Uptal Patel, MD, as Chief Medical Officer! Uptal joins HI-Bio from AstraZeneca where he served as the Head of Clinical Renal and Executive Group Director in Early Cardiovascular, Renal and Metabolism (CVRM). We look forward to working with Uptal to accelerate our clinical programs in Primary Membranous Nephropathy and across the immune-mediated disease landscape.
 
We are also excited to welcome Sunil Agarwal, MD, to our Board of Directors. Sunil was most recently Executive Vice President, Head of Development and Chief Medical Officer at Sana Biotechnology. His deep experience in clinical development and with the drug approval process will invaluable as we advance our pipeline.
 
Learn more about Uptal and Sunil’s backgrounds and the value they bring to our team: https://lnkd.in/e2iKTKWr
 
#PrimaryMembranousNephropathy #immunemediateddisease

We are excited to share positive Phase 2 data from two studies of felzartamab for the treatment of Primary Membranous Nephropathy (PMN). The studies showed reduction in pathogenic antibody levels and proteinuria remissions that may signal renal recovery.
 
PMN is a rare immune-mediated disease (IMD) of the kidney that impacts more than 36,000 patients in the United States, and over 4,000 new patients every year. PMN imposes a high burden on patients and is one of the most common causes of nephrotic syndrome. There are currently no approved therapies for PMN.
 
We are focused on developing felzartamab in PMN and other IMDs to address patients’ significant unmet needs. Learn more about the studies: https://lnkd.in/eWVX7ZQE

#PrimaryMembranousNephropathy #felzartamab #immunemediateddisease

Few targeted therapies exist for immune-mediated disease (IMDs), including autoimmune diseases. As #AutoimmuneAwarenessMonth comes to a close, learn more about our lead program, felzartamab, and how we are targeting the cellular drivers of disease to develop precision therapies for patients in need. https://hibio.com

March is #NationalKidneyMonth and today is #WorldKidneyDay, dedicated to raising awareness around the importance of kidney health, especially rare, immune-mediated diseases like Membranous Nephropathy and IgA Nephropathy.
 
We are dedicated to developing targeted therapies to treat these diseases and more through our precision medicine approach. Through our commitment to achieve better results for patients affected by IMDs, we are leading clinical immunology into its next chapter.

Viewport Meta

IPhone / Mobile Compatible

Google Tag Manager

Apple Mobile Web Clips Icon

WordPress

Font Awesome

Organization Schema

Sitelinks Search Box

Yoast WordPress SEO Plugin

Yoast Plugins

VP, Global Scientific Operations

Elizabeth Liz

SVP, Global Head of Research

Francisco Adrian

VP, Head of Research, France & Global CMC

Nicola Beltraminelli

Executive Director, Global Head of Drug Intelligent Science

Andreas Raue

Sr. Director, Head of DIS France & EU Ext. Innovation

Annabelle Gerard

Healthcare

Gabrielle Wong

Human Resources

Liwen Y.

Engineering

Roshan Kumar

Senior Director, Head of US Drug Intelligent Science and External Innovation

Director, Global Head of Scientific Operations

Stephen Beauparlant

Ryan Jeong

Robert Nicol

Co-Founder

Jeff He

Chief Operating Officer

Fred Dom

Chief Financial Officer

Head of Drug Sciences and Vice President

Franciscc Adrian

Head of Global Disease Biology and Vice President

Head of External Innovation and Senior Director

Robert G. Petit

Senior Medical & Scientific Advisor

Edward Garmey

Interim CMO

Pharmaceutical Companies With Fewer Than 1000 Employees (Top 10K)

LYFE Capital Portfolio Companies

Ile-de-France Companies With More Than 50 Employees

Companies With Less Than $500M in Revenue (Top 10K)

HiFiBiO is a biotherapeutics company that mobilizes the human immune system to combat disease. It commercializes proprietary single-cell technologies for applications in drug and biomarker discovery and development. It also aspires to benefit patients through open-innovation partnerships with industry and academia. HiFiBiO integrates deep-rooted biological expertise with its comprehensive single-cell profiling technologies to discover and accelerate a pipeline of antibody drugs to treat cancer and autoimmune disorders.

The company was founded in 2013 and is headquartered in Paris, Ille-de-France.

Mirae Asset Capital

Series D - HiFiBiO

IDG Capital

Series C - HiFiBiO

Venture Round - HiFiBiO

HongShan

LYFE Capital

Series B - HiFiBiO

Series A - HiFiBiO

Paris

Ile-de-France

France

Europe

HiFiBiO

Introducing Fierce Biotech's 2023 Fierce 15

HiFiBiO gets high-five from investors with $75M series D to bring two programs into clinic

Anti-Galectin-9 antibody and uses thereof

Kite Partners to Develop Leukemia Treatments

HiFiBiO Therapeutics Returns to VC Well, Raising $67 Million Series C

Kite partner HiFiBiO closes $67M round for preclinical antibody candidates churned out of single-cell analytics platform

A first-in-class agonistic anti-TNFR2 antibody designed for the treatment of solid tumors, showing potent antitumor activity and well-tolerated in preclinical studies.

A novel fully human IgG1 class OX-40 agonistic antibody optimized for enhanced clinical activity in treating solid tumors, demonstrating superior anti-tumor activity in preclinical models.

An antagonist antibody targeting BTLA to restore anti-tumor immunity, showing synergistic effects with anti-PD-1 and favorable pharmacokinetic profiles in preclinical studies.

An anti-Gal-9 blocking antibody intended for the treatment of myeloid malignancies and solid tumors, with demonstrated single-agent anti-tumor activity and improved survival in combination with anti-PD-1 therapy in preclinical models.

A humanized monoclonal antibody against CCR8 with potent ADCC activity, designed to deplete immunosuppressive Tregs in the tumor microenvironment and promote anti-tumor immunity.

A humanized afucosylated IgG1 antibody targeting CXCR5 for the potential treatment of B cell lymphomas and autoimmune diseases, capable of selectively depleting CXCR5+ B and T follicular helper cells.

India

Asia

United States

North America

Bangladesh

HTML5

jQuery

Google Analytics

Apache Server

Gravity Forms

Wordpress

Microsoft Outlook

HiFiBiO owns HiFiBiO Cambridge

Human Immunology Biosciences (HI-Bio™) is a clinical-stage biotechnology company developing precision therapies for patients with severe immune-mediated diseases (IMDs). The company aims to address the high unmet medical needs in autoimmune, allergic, and inflammatory diseases through targeted therapies that target the dysfunction of cells in the immune system. HI-Bio leverages human genetic and immunological insights to deliver novel treatments for IMDs.

news impact assignment basic	general
public peers	general
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general
crunchbase trigger	general	Nov 25, 2024 9:06 AM	47d4fd88
crunchbase profile	general	Nov 25, 2024 12:05 PM	4c12a99e
li profile	general	Jan 29, 2024 3:59 PM	bd66bb91
translate crunchbase fundingrounds	general	Nov 25, 2024 1:51 PM	9b663ba7
peers	general
news basic	general
bundesanzeiger	filings
financials download nd	financials
private financials	financials

COM:HIBIO

Human Immunology Biosciences